A study tested carboxyfullerene (C3), a water-soluble derivative of [60]fullerene (C60), for its ability to protect brain function in macaque monkeys with Parkinson’s-like symptoms induced by MPTP, a toxin that mimics the disease. This was the first in vivo test of C3 as a neuroprotective agent in a Parkinson’s model.

Key Findings:

• Improved Movement: Monkeys treated with C3 for two months, starting one week after MPTP exposure, showed better motor skills, with less parkinsonism (tremors and stiffness) compared to the placebo group.
• Brain Protection: C3-treated monkeys had higher levels of dopamine (a key brain chemical reduced in Parkinson’s), better uptake of markers for dopamine production and storage (seen via PET imaging), and more surviving dopamine-producing neurons in the brain.
• Safe and Effective: C3 caused no toxicity and reduced brain damage even when given after injury began, highlighting its potential as a treatment.
• Antioxidant Action: C3’s ability to neutralize harmful oxygen radicals likely helped protect brain cells from further degeneration.

Why It Matters for Consumers: For those interested in C60 and its health benefits, this study shows that a C60 derivative could help slow or reverse Parkinson’s disease progression by protecting brain cells. This offers hope for safer, more effective treatments for Parkinson’s, a condition that affects movement and quality of life.

Takeaway: Carboxyfullerene (C3) is a promising, non-toxic therapy that improves motor function and preserves brain health in a Parkinson’s model. While more research is needed to bring it to patients, this study marks a significant step toward new treatments for neurodegenerative diseases.

Link to research

• Carboxyfullerene neuroprotection post injury in parkinsonian nonhuman primates